Abstract
OBJECTIVE We aimed to compare cardiovascular (CV) events, all-cause mortality, and CV mortality rates among adults with and without diabetes in countries with differing levels of income. RESEARCH DESIGN AND METHODS The Prospective Urban Rural Epidemiology (PURE) study enrolled 143,567 adults aged 35–70 years from 4 high-income countries (HIC), 12 middle-income countries (MIC), and 5 low-income countries (LIC). The mean follow-up was 9.0 ± 3.0 years. RESULTS Among those with diabetes, CVD rates (LIC 10.3, MIC 9.2, HIC 8.3 per 1,000 person-years, P < 0.001), all-cause mortality (LIC 13.8, MIC 7.2, HIC 4.2 per 1,000 person-years, P < 0.001), and CV mortality (LIC 5.7, MIC 2.2, HIC 1.0 per 1,000 person-years, P < 0.001) were considerably higher in LIC compared with MIC and HIC. Within LIC, mortality was higher in those in the lowest tertile of wealth index (low 14.7%, middle 10.8%, and high 6.5%). In contrast to HIC and MIC, the increased CV mortality in those with diabetes in LIC remained unchanged even after adjustment for behavioral risk factors and treatments (hazard ratio [95% CI] 1.89 [1.58–2.27] to 1.78 [1.36–2.34]). CONCLUSIONS CVD rates, all-cause mortality, and CV mortality were markedly higher among those with diabetes in LIC compared with MIC and HIC with mortality risk remaining unchanged even after adjustment for risk factors and treatments. There is an urgent need to improve access to care to those with diabetes in LIC to reduce the excess mortality rates, particularly among those in the poorer strata of society.
Original language | English |
---|---|
Pages (from-to) | 3094-3101 |
Number of pages | 8 |
Journal | Diabetes Care |
Volume | 43 |
Issue number | 12 |
DOIs | |
Publication status | Published - 2020 |
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Contrasting associations between diabetes and cardiovascular mortality rates in low-, middle-, and high-income countries: Cohort study data from 143,567 individuals in 21 countries in the pure study'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Diabetes Care, Vol. 43, No. 12, 2020, p. 3094-3101.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Contrasting associations between diabetes and cardiovascular mortality rates in low-, middle-, and high-income countries
T2 - Cohort study data from 143,567 individuals in 21 countries in the pure study
AU - Anjana, Ranjit Mohan
AU - Mohan, Viswanathan
AU - Rangarajan, Sumathy
AU - Gerstein, Hertzel C.
AU - Venkatesan, Ulagamadesan
AU - Sheridan, Patrick
AU - Dagenais, Gilles R.
AU - Lear, Scott A.
AU - Teo, Koon
AU - Karsidag, Kubilay
AU - Alhabib, Khalid F.
AU - Yusoff, Khalid
AU - Ismail, Noorhassim
AU - Mony, Prem K.
AU - Lopez-Jaramillo, Patricio
AU - Chifamba, Jephat
AU - Palileo-Villanueva, Lia M.
AU - Iqbal, Romaina
AU - Yusufali, Afzalhussein
AU - Kruger, Iolanthe M.
AU - Rosengren, Annika
AU - Bahonar, Ahmad
AU - Zatonska, Katarzyna
AU - Yeates, Karen
AU - Gupta, Rajeev
AU - Li, Wei
AU - Hu, Lihua
AU - Rahman, M. Omar
AU - Lakshmi, P. V.M.
AU - Iype, Thomas
AU - Avezum, Alvaro
AU - Diaz, Rafael
AU - Lanas, Fernando
AU - Yusuf, Salim
N1 - Funding Information: Acknowledgments. The authors acknowledge the contribution of the PURE Project Office Staff, National Coordinators, Investigators, and Key Staff. A complete list of the contributors and the institutions in each country is found in the Supplementary Material online. Argentina: Fundacion Estudios Clíni-cos Latino America; Bangladesh: Independent University, Bangladesh and Mitra and Associates; Brazil: Unilever Health Institute, Brazil; Canada: Public Health Agency of Canada and Champlain Cardiovascular Disease Prevention Network; Chile: Universidad de la Frontera; China: National Center for Cardiovascular Diseases and ThinkTank Research Center for Health Development; Colombia: Colciencias (grant 6566-04-18062 and grant 6517-777-58228); India: Indian Council of Medical Research;Malaysia:MinistryofScience,Technology andInnovationofMalaysia(grant100-IRDC/BIOTEK 16/6/21[13/2007]and07-05-IFN-BPH010),Ministry of Higher Education of Malaysia (grant 600-RMI/ LRGS/5/3 [2/2011]), Universiti Teknologi MARA, Universiti Kebangsaan Malaysia (UKM-Hejim-Komuniti-15-2010); Occupied Palestinian Territory: the United Nations Relief and Works Agency for Palestine Refugees in the Near East, International Development Research Centre, Canada; Philippines: Philippine Council for Health Research and Development; Poland: Polish Ministry of Science and Higher Education (grant 290/W-PURE/2008/0), Wroclaw Medical University; Saudi Arabia: Saudi Heart Association, Dr. Mohammad Alfagih Hospital, The Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia (research group RG-1436-013); South Africa: The North-West University, South African-Netherlands Programme for Alternatives in Development, National Research Foundation, Medical Research Council of South Africa, The SouthAfricaSugarAssociation,Faculty of Community and Health Sciences; Sweden: grants from the Swedish state under the Agreement concerning research and education of doctors, the SwedishHeartandLungFoundation,theSwedish Research Council, the Swedish Council for Health, WorkingLifeandWelfare,KingGustafV’sandQueen Victoria Freemasons’ Foundation, AFA Insurance; Turkey:MetabolicSyndromeSociety,AstraZeneca, Sanofi Aventis; United Arab Emirates: Sheikh Ham-dan Bin Rashid Al Maktoum Award For Medical Sciences and Dubai Health Authority, Dubai. Funding and Duality of Interest. S.Y. is supported by the Marion W. Burke endowed chair of the Heart and Stroke Foundation of Ontario. This work was supported by the Population Health Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, support from Canadian Institutes of Health Research’s Strategy for Patient-Oriented Research, through the Ontario Strategy for Patient-Oriented Research Support Unit, as well as the Ontario Ministry of Health and Long-Term Care and through unrestricted grants from several pharmaceutical companies with major contributions from AstraZeneca (Canada), Sanofi (France and Canada), Boehringer Ingelheim (Germany and Canada), Servier, and Glaxo-SmithKline, and additional contributions from Novartis and King Pharma and from various national or local organizations in participating countries. No other potential conflicts of interest relevant to this article were reported. Funding Information: The authors acknowledge the contribution of the PURE Project Office Staff, National Coordinators, Investigators, and Key Staff. A complete list of the contributors and the institutions in each country is found in the Supplementary Material online. Argentina: Fundacion Estudios Clínicos Latino America; Bangladesh: Independent Uni-versity, Bangladesh and Mitra and Associates; Brazil: Unilever Health Institute, Brazil; Canada: Public Health Agency of Canada and Champlain Cardiovascular Disease Prevention Network; Chile: Universidad de la Frontera; China: National Center for Cardiovascular Diseases and ThinkTank Research Center for Health Development; Colombia: Colciencias (grant 6566-04-18062 and grant 6517-777-58228); India: Indian Council of Medical Research; Malaysia: Ministry of Science, Technology and Innovation of Malaysia (grant 100-IRDC/BIOTEK 16/6/21[13/2007] and07-05-IFN-BPH010), Ministry of Higher Education of Malaysia (grant 600-RMI/ LRGS/5/3 [2/2011]), Universiti Teknologi MARA, Universiti Kebangsaan Malaysia (UKM-Hejim-Komuniti-15-2010); Occupied Palestinian Territory: the United Nations Relief and Works Agency for Palestine Refugees in the Near East, International Development Research Centre, Canada; Philippines: Philippine Council for Health Research and Devel-opment; Poland: Polish Ministry of Science and Higher Education (grant 290/W-PURE/2008/0), Wroclaw Medical University; Saudi Arabia: Saudi Heart Association, Dr. Mohammad Alfagih Hospital, The Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia (research group RG-1436-013); South Africa: The North-West University, South African-Netherlands Programme for Alternatives in Development, National Research Foundation, Medical Research Council of South Africa, The South Africa Sugar Association, Faculty of Community and Health Sciences; Sweden: grants from the Swedish state under the Agreement con-cerning research and education of doctors, the Swedish Heart and Lung Foundation, the Swedish Research Council, the Swedish Council for Health, WorkingLifeandWelfare, KingGustaf V’s andQueen Victoria Freemasons’ Foundation, AFA Insurance; Turkey: Metabolic Syndrome Society, AstraZeneca, Sanofi Aventis; United Arab Emirates: Sheikh Hamdan Bin Rashid Al Maktoum Award For Medical Sciences and Dubai Health Authority, Dubai. Funding and Duality of Interest. S.Y. is supported by the Marion W. Burke endowed chair of the Heart and Stroke Foundation of Ontario. This work was supported by the Population Health Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, support from Canadian Institutes of Health Research’s Strategy for Patient-Oriented Research, through the Ontario Strategy for Patient-Oriented Research Support Unit, as well as the Ontario Ministry of Health and Long-Term Care and through unrestricted grants from several pharmaceutical companies with major contributions from AstraZeneca (Canada), Sanofi (France and Canada), Boehringer Ingelheim (Germany and Canada), Servier, and Glaxo-SmithKline, and additional contributions from Novartis and King Pharma and from various national or local organizations in participating countries. No other potential conflicts of interest relevant to this article were reported. The funders and sponsors had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, in the prep-aration, review, or approval of the manuscript, or in the decision to submit the manuscript for publication. Publisher Copyright: © 2020 by the American Diabetes Association.
PY - 2020
Y1 - 2020
N2 - OBJECTIVE We aimed to compare cardiovascular (CV) events, all-cause mortality, and CV mortality rates among adults with and without diabetes in countries with differing levels of income. RESEARCH DESIGN AND METHODS The Prospective Urban Rural Epidemiology (PURE) study enrolled 143,567 adults aged 35–70 years from 4 high-income countries (HIC), 12 middle-income countries (MIC), and 5 low-income countries (LIC). The mean follow-up was 9.0 ± 3.0 years. RESULTS Among those with diabetes, CVD rates (LIC 10.3, MIC 9.2, HIC 8.3 per 1,000 person-years, P < 0.001), all-cause mortality (LIC 13.8, MIC 7.2, HIC 4.2 per 1,000 person-years, P < 0.001), and CV mortality (LIC 5.7, MIC 2.2, HIC 1.0 per 1,000 person-years, P < 0.001) were considerably higher in LIC compared with MIC and HIC. Within LIC, mortality was higher in those in the lowest tertile of wealth index (low 14.7%, middle 10.8%, and high 6.5%). In contrast to HIC and MIC, the increased CV mortality in those with diabetes in LIC remained unchanged even after adjustment for behavioral risk factors and treatments (hazard ratio [95% CI] 1.89 [1.58–2.27] to 1.78 [1.36–2.34]). CONCLUSIONS CVD rates, all-cause mortality, and CV mortality were markedly higher among those with diabetes in LIC compared with MIC and HIC with mortality risk remaining unchanged even after adjustment for risk factors and treatments. There is an urgent need to improve access to care to those with diabetes in LIC to reduce the excess mortality rates, particularly among those in the poorer strata of society.
AB - OBJECTIVE We aimed to compare cardiovascular (CV) events, all-cause mortality, and CV mortality rates among adults with and without diabetes in countries with differing levels of income. RESEARCH DESIGN AND METHODS The Prospective Urban Rural Epidemiology (PURE) study enrolled 143,567 adults aged 35–70 years from 4 high-income countries (HIC), 12 middle-income countries (MIC), and 5 low-income countries (LIC). The mean follow-up was 9.0 ± 3.0 years. RESULTS Among those with diabetes, CVD rates (LIC 10.3, MIC 9.2, HIC 8.3 per 1,000 person-years, P < 0.001), all-cause mortality (LIC 13.8, MIC 7.2, HIC 4.2 per 1,000 person-years, P < 0.001), and CV mortality (LIC 5.7, MIC 2.2, HIC 1.0 per 1,000 person-years, P < 0.001) were considerably higher in LIC compared with MIC and HIC. Within LIC, mortality was higher in those in the lowest tertile of wealth index (low 14.7%, middle 10.8%, and high 6.5%). In contrast to HIC and MIC, the increased CV mortality in those with diabetes in LIC remained unchanged even after adjustment for behavioral risk factors and treatments (hazard ratio [95% CI] 1.89 [1.58–2.27] to 1.78 [1.36–2.34]). CONCLUSIONS CVD rates, all-cause mortality, and CV mortality were markedly higher among those with diabetes in LIC compared with MIC and HIC with mortality risk remaining unchanged even after adjustment for risk factors and treatments. There is an urgent need to improve access to care to those with diabetes in LIC to reduce the excess mortality rates, particularly among those in the poorer strata of society.
UR - http://www.scopus.com/inward/record.url?scp=85096491166&partnerID=8YFLogxK
U2 - 10.2337/dc20-0886
DO - 10.2337/dc20-0886
M3 - Article
C2 - 33060076
AN - SCOPUS:85096491166
SN - 0149-5992
VL - 43
SP - 3094
EP - 3101
JO - Diabetes Care
JF - Diabetes Care
IS - 12
ER -